The drugmakers said they expect to start clinical trials for the vaccine in the second half of this year. If successful, the vaccine would be available in the second half of 2021. The announcement comes at a time when drugmakers are pausing clinical trials for other disease areas as they focus on testing potential treatments for the coronavirus. The adjuvanted vaccine will be developed by combining Sanofi's S-protein COVID-19 antigen and GSK's pandemic adjuvant technology. An adjuvant is added to some vaccines to enhance the immune response, and has been shown to create a stronger and longer lasting immunity against infections than the vaccine alone.

Source: bd News24 April 14, 2020 10:52 UTC